LLM BSc - Purple Biotech Vice Operations
| PPBT Stock | USD 0.51 0 0.39% |
Executive
LLM BSc is Vice Operations of Purple Biotech
| Age | 52 |
| Address | 4 Oppenheimer Street, Rehovot, Israel, 7670104 |
| Phone | 972 3 933 3121 |
| Web | https://purple-biotech.com |
Purple Biotech Management Efficiency
The company has return on total asset (ROA) of (0.2907) % which means that it has lost $0.2907 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4826) %, meaning that it created substantial loss on money invested by shareholders. Purple Biotech's management efficiency ratios could be used to measure how well Purple Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.28 in 2024. Return On Capital Employed is likely to drop to -0.63 in 2024. At this time, Purple Biotech's Non Current Liabilities Total is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 964.8 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 3.7 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jeffrey Cole | Cadrenal Therapeutics Common | N/A | |
| Robert Ticktin | Pmv Pharmaceuticals | 62 | |
| FACC FAHA | Cadrenal Therapeutics Common | 66 | |
| Daniel George | Anebulo Pharmaceuticals | 54 | |
| Raul MD | Cingulate | 66 | |
| Patricia Hirano | Soleno Therapeutics | 58 | |
| Tim Smith | Pmv Pharmaceuticals | N/A | |
| MD DFAPA | Bionomics Ltd ADR | N/A | |
| FCA BEC | Bionomics Ltd ADR | 71 | |
| Kristen MS | Soleno Therapeutics | 55 | |
| Binh Vu | Pmv Pharmaceuticals | N/A | |
| MBA Ashizawa | Bio Path Holdings | N/A | |
| Jeff Cole | Cadrenal Therapeutics Common | N/A | |
| Crystal Zuckerman | Pmv Pharmaceuticals | N/A | |
| Michael Carulli | Pmv Pharmaceuticals | N/A | |
| Carlos Carillo | SAB Biotherapeutics | N/A | |
| Thomas Dalton | Cingulate | N/A | |
| Veronique AmorBaroukh | Enlivex Therapeutics | N/A | |
| FCIS BCom | Bionomics Ltd ADR | N/A | |
| Efrat LivneHadass | Pluri Inc | N/A | |
| Matthew MD | Cingulate | 60 | |
Management Performance
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.29 |
Purple Biotech Leadership Team
Elected by the shareholders, the Purple Biotech's board of directors comprises two types of representatives: Purple Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Purple. The board's role is to monitor Purple Biotech's management team and ensure that shareholders' interests are well served. Purple Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Purple Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MA CPA, Chief Officer | ||
| Fabien Sebille, Chief Officer | ||
| Michael Schickler, Head Affairs | ||
| LLM BSc, Vice Operations | ||
| Ido Morpurgo, VP Operations | ||
| Nir Livneh, VP Affairs |
Purple Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Purple Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 3.22 M | ||||
| Shares Outstanding | 26.11 M | ||||
| Shares Owned By Insiders | 3.82 % | ||||
| Shares Owned By Institutions | 9.50 % | ||||
| Number Of Shares Shorted | 309.87 K | ||||
| Price To Book | 0.47 X | ||||
| Price To Sales | 58.08 X | ||||
| Gross Profit | (120 K) |
Pair Trading with Purple Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Purple Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Purple Biotech will appreciate offsetting losses from the drop in the long position's value.Moving against Purple Stock
The ability to find closely correlated positions to Purple Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Purple Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Purple Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Purple Biotech to buy it.
The correlation of Purple Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Purple Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Purple Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Purple Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Purple Stock Analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.